Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,800

Employees1,800

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,800

Employees1,800

NBIX Key Statistics

Market cap

13.57B

Market cap13.57B

Price-Earnings ratio

32.49

Price-Earnings ratio32.49

Dividend yield

—

Dividend yield—

Average volume

937.45K

Average volume937.45K

High today

$137.53

High today$137.53

Low today

$134.96

Low today$134.96

Open price

$137.53

Open price$137.53

Volume

966.49K

Volume966.49K

52 Week high

$160.18

52 Week high$160.18

52 Week low

$84.23

52 Week low$84.23

Stock Snapshot

With a market cap of 13.57B, Neurocrine(NBIX) trades at $136.06. The stock has a price-to-earnings ratio of 32.49.

On 2026-01-31, Neurocrine(NBIX) stock moved within a range of $134.96 to $137.53. With shares now at $136.06, the stock is trading +0.8% above its intraday low and -1.1% below the session's peak.

Trading activity shows a volume of 966.49K, compared to an average daily volume of 937.45K.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

NBIX News

Simply Wall St 8h

Neurocrine Biosciences Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update

Advertisement Why this new trial matters for Neurocrine Biosciences (NBIX) shareholders Neurocrine Biosciences (NBIX) has kicked off a Phase 2 trial of NBI-10...

TipRanks 2d

Neurocrine price target raised to $195 from $191 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Neurocrine (NBIX) to $195 from $191 and keeps a Buy rating on the shares as part of the firm’s Q4 sm...

Simply Wall St 4d

Does Neurocrine Biosciences Price Weakness Signal A Long Term Opportunity?

If you are wondering whether Neurocrine Biosciences is attractively priced or already reflecting its potential, starting with a clear view of value can help fra...

Analyst ratings

87%

of 30 ratings

Buy

86.7%

Hold

13.3%

Sell

More NBIX News

TipRanks 6d

Neurocrine initiates Phase 2 study of NBI-1065890 in adults with TD

Neurocrine (NBIX) Biosciences announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia....

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Alnylam Pharmaceuticals

TE Connectivity

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.